Recent reports from Zhang et al. [9] and Toblli et al. [10] show that angiotensin-converting enzyme (ACE) inhibitors prevent not only liver-related events in NAFLD in humans but also fatty liver and fibrosis in an obese zucker NASH rat model. Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.